Compare WIA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | PLX |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.5M | 174.0M |
| IPO Year | N/A | 1996 |
| Metric | WIA | PLX |
|---|---|---|
| Price | $8.08 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 49.5K | ★ 1.0M |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $37.52 |
| Revenue Next Year | N/A | $1.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.95 | $1.34 |
| 52 Week High | $8.54 | $3.19 |
| Indicator | WIA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 37.78 |
| Support Level | N/A | $2.03 |
| Resistance Level | $8.31 | $2.45 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 45.83 | 15.17 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.